Traders Buy High Volume of Boston Scientific Put Options (NYSE:BSX)

Boston Scientific Corporation (NYSE:BSX) was the recipient of unusually large options trading activity on Wednesday. Traders purchased 65,788 put options on the stock. This is an increase of 205% compared to the typical daily volume of 21,596 put options.

Boston Scientific Stock Performance

NYSE BSX opened at $62.73 on Friday. The stock has a market cap of $93.23 billion, a PE ratio of 32.34, a P/E/G ratio of 0.96 and a beta of 0.78. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The firm has a 50-day moving average of $75.21 and a 200-day moving average of $89.65. Boston Scientific has a 52-week low of $61.24 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. The business had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. Boston Scientific’s quarterly revenue was up 15.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, sell-side analysts anticipate that Boston Scientific will post 2.85 EPS for the current year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.50% of the company’s stock.

Hedge Funds Weigh In On Boston Scientific

Large investors have recently made changes to their positions in the company. Steph & Co. acquired a new stake in shares of Boston Scientific during the third quarter worth $25,000. Financial Consulate Inc. acquired a new position in shares of Boston Scientific in the third quarter valued at about $25,000. Murphy & Mullick Capital Management Corp increased its position in Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 170 shares during the period. FWL Investment Management LLC bought a new position in Boston Scientific during the second quarter worth about $26,000. Finally, Swiss RE Ltd. acquired a new stake in Boston Scientific in the 4th quarter worth about $26,000. Institutional investors own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on BSX shares. JPMorgan Chase & Co. dropped their target price on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. UBS Group reduced their price target on Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a report on Tuesday, March 17th. Morgan Stanley lowered their price target on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Sanford C. Bernstein restated an “outperform” rating and issued a $112.00 price objective on shares of Boston Scientific in a research note on Friday, February 6th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $115.00 price objective on shares of Boston Scientific in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $104.36.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: CHAMPION‑AF trial met all primary and secondary endpoints — clinical data supporting the WATCHMAN FLX device reduces stroke risk versus NOACs, which can drive adoption and revenue confidence. Boston Scientific (BSX) Says CHAMPION-AF Trial Meets All Primary Endpoints
• Positive Sentiment: Completed acquisition of Valencia Technologies — a strategic tuck‑in that expands diagnostic/therapy capabilities and supports medium‑term growth execution. Boston Scientific completes Valencia Technologies acquisition
• Positive Sentiment: Analyst support remains: Needham and Raymond James reconfirmed bullish ratings and RBC called Boston Scientific’s 2026 guidance “reasonable,” which helps counter bearish sentiment and supports valuation. Needham & Company LLC Reaffirms “Buy” Rating for Boston Scientific (NYSE:BSX) Boston Scientific’s 2026 Guidance ‘Reasonable’, RBC Says
• Neutral Sentiment: Longer-term bullish research pieces highlight BSX as a growth/compounder — useful for buy-and-hold investors but less likely to move near‑term price. Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
• Negative Sentiment: Multiple law firms have filed/are soliciting plaintiffs in a securities class action tied to disclosures covering July 23, 2025–Feb 3, 2026, with a May 4, 2026 lead‑plaintiff deadline — this legal overhang increases uncertainty and downside risk. BOSTON SCIENTIFIC CORPORATION (BSX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Boston Scientific Corporation Investors of Upcoming Deadline
• Negative Sentiment: Unusually large put‑option activity (65,788 puts traded, ~205% above normal) suggests some traders are positioning for downside or hedging — a short-term bearish signal.
• Negative Sentiment: Recent analyst downgrade drove BSX to a new 12‑month low earlier in the week, highlighting continued sensitivity to earnings/guidance and sentiment swings. Boston Scientific (NYSE:BSX) Reaches New 12-Month Low After Analyst Downgrade

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.